SEATTLE — Supporters of a police pursuit initiative announced Thursday it has received enough signatures for the 2024 ballot. Initiative 2113 would amend the state's controversial police pursuit law ...
Janssen, a Johnson & Johnson company, has announced positive topline results from its Phase 2b FRONTIER 1 trial evaluating JNJ-2113, a novel first-and-only oral interleukin-23 receptor antagonist ...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the ...
The ICONIC program now includes four Phase 3 studies evaluating JNJ-2113; Co-primary endpoints for all four studies are PASI-90 and/or IGA 0 or 1 Protagonist eligible to receive $115 million milestone ...
Takeda gained the drug in 2019 in its purchase of specialty drug-maker Shire Plc. Janssen Pharmaceuticals recently announced its latest clinical trial results of JNJ-2113, the novel, first-in-class ...
JNJ-2113 achieved all primary and secondary endpoints in the Phase 2b clinical trial FRONTIER 1, including PASI 100 and IGA 0 responses of 40.5 percent and 45.2 percent, respectively. JNJ-2113 is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results